- Home
- AZ vs ARCT Comparison
AZ vs ARCT Comparison
Compare AZ & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | ARCT |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.5M | 194.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AZ | ARCT |
|---|---|---|
| Price | $6.48 | $6.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $20.00 | ★ $38.67 |
| AVG Volume (30 Days) | 475.6K | ★ 706.5K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,463,000.00 | ★ $97,601,000.00 |
| Revenue This Year | $1,343,857.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 41.45 | N/A |
| 52 Week Low | $5.00 | $5.85 |
| 52 Week High | $12.36 | $24.17 |
Technical Indicators
Market Signals| Indicator | AZ | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 33.00 |
| Support Level | $5.64 | $6.34 |
| Resistance Level | $6.59 | $6.75 |
| Average True Range (ATR) | 0.47 | 0.36 |
| MACD | 0.09 | 0.10 |
| Stochastic Oscillator | 75.00 | 5.02 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.